Member Publications - 1995

January

  1. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S74-82.

  2. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, Moss RB, Daigle A, Richieri SP, Jensen F, Carlo DJ. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S51-6. Review.

February

March

  1. Alternative pharmacotherapies for steroid-dependent asthma. Moss RB. Chest. 1995 Mar;107(3):817-25. Review.

  2. Ca(2+)-inhibitable adenylyl cyclase modulates pulmonary artery endothelial cell cAMP content and barrier function. Stevens T, Nakahashi Y, Cornfield DN, McMurtry IF, Cooper DM, Rodman DM. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2696-700.

  3. Gene therapy vectors as drug delivery systems. Afione SA, Conrad CK, Flotte TR. Clin Pharmacokinet. 1995 Mar;28(3):181-9. Review.

April

  1. Hypoxia potentiates nitric oxide synthesis and transiently increases cytosolic calcium levels in pulmonary artery endothelial cells. Hampl V, Cornfield DN, Cowan NJ, Archer SL. Eur Respir J. 1995 Apr;8(4):515-22.

  2. New drugs for cystic fibrosis lung disease. Moss RB. West J Med. 1995 Apr;162(4):354-5. 

May

  1. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Moss RB, King VV. Arch Otolaryngol Head Neck Surg. 1995 May;121(5):566-72.

June

  1. Activation of CFTR chloride current by nitric oxide in human T lymphocytes. Dong YJ, Chao AC, Kouyama K, Hsu YP, Bocian RC, Moss RB, Gardner P. EMBO J. 1995 Jun 15;14(12):2700-7.

July

August

September

October

  1. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Moss RB. Clin Infect Dis. 1995 Oct;21(4):839-49; quiz 850-1. Review. 

November

December